Take a deep breath, Primary endpoint isnt the be all end all, particularly if its due to the placebo group improving to a point where we dont have the opportunity to be statistically significant (even if 100% of treatment arm recovered, which is likely)

In a phase 2b/3 you can lean on secondary endpoints. Good data is coming. I dont know how much more clearly Nader can say it (other than publishing the data)